SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2024

SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

SUPPLEMENTARY FINANCIAL DATA

(UNAUDITED)

(In thousands, except per share data)

The following table presents certain unaudited consolidated quarterly financial information for the eight quarters in the periods ended December 31, 2024 and 2023. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein.

	For the Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2024
Total revenue	$	14,503	$	14,256	$	16,868	$	18,754
Total expenses		25,710		29,961		27,705		27,954
Loss from operations		(11,207)		(15,705)		(10,837)		(9,200)
Net loss		(11,664)		(16,529)		(12,698)		(15,527)
Net loss - basis and diluted per share	$	(0.24)	$	(0.34)	$	(0.26)	$	(0.31)
2023
Total revenue	$	10,417	$	13,749	$	15,693	$	17,565
Total expenses		35,329		29,872		24,453		23,805
Loss from operations		(24,912)		(16,123)		(8,760)		(6,240)
Net loss		(22,088)		(15,645)		(8,950)		(8,510)
Net loss - basis and diluted per share	$	(0.35)		(0.28)		(0.17)		(0.17)
Share of Total YUPELRI Net Sales (1)
	For the Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2024	$	19,329	$	19,085	$	21,766	$	23,339
2023	$	16,434	$	19,263	$	20,414	$	21,225

(1) The Company co-promotes YUPELRI in the US under a profit and loss sharing arrangement with Viatris (65% to Viatris; 35% to Theravance Biopharma). The amounts represent the Company’s implied 35% share of the total net sales of YUPELRI that were recognized within Viatris’ financial statements for the periods presented.